Latest news with #Denmark-based
Yahoo
11 hours ago
- Business
- Yahoo
Saint-Gobain acquires Maturix to expand digital construction reach
French multinational Saint-Gobain has acquired Denmark-based real-time concrete monitoring solutions provider Maturix, marking a significant step in the expansion of its digital construction chemicals platform. Maturix's wireless sensor technology facilitates remote monitoring of concrete properties during the curing and hardening process, which can halve the duration of the concrete construction cycle and enhance job-site efficiency. The integration of the Danish company into Saint-Gobain's portfolio strengthens the company's digital offerings across the concrete and cement value chains. Saint-Gobain customers can now benefit from reduced overdesign and optimised operations, contributing to the digital transformation of the concrete industry. This move follows Saint-Gobain's initiatives such as the deployment of Verifi, its digital in-transit concrete management suite, across North America, Europe, and Asia-Pacific. Verifi's real-time monitoring capabilities are designed to minimise waste, boost operational performance, and drive cost efficiencies. The addition of Maturix's technology is expected to complement Verifi's system, particularly in optimising concrete placement on construction sites. Since 2019, Maturix and Saint-Gobain have collaborated successfully, and they are currently developing a joint product offering. Earlier this year, Saint-Gobain completed the acquisition of FOSROC, a construction chemicals company, which further solidified Saint-Gobain's position in the global market, enhancing its capabilities in the construction chemicals sector. "Saint-Gobain acquires Maturix to expand digital construction reach" was originally created and published by World Construction Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 hours ago
- Business
- Yahoo
Saint-Gobain acquires Maturix to expand digital construction reach
French multinational Saint-Gobain has acquired Denmark-based real-time concrete monitoring solutions provider Maturix, marking a significant step in the expansion of its digital construction chemicals platform. Maturix's wireless sensor technology facilitates remote monitoring of concrete properties during the curing and hardening process, which can halve the duration of the concrete construction cycle and enhance job-site efficiency. The integration of the Danish company into Saint-Gobain's portfolio strengthens the company's digital offerings across the concrete and cement value chains. Saint-Gobain customers can now benefit from reduced overdesign and optimised operations, contributing to the digital transformation of the concrete industry. This move follows Saint-Gobain's initiatives such as the deployment of Verifi, its digital in-transit concrete management suite, across North America, Europe, and Asia-Pacific. Verifi's real-time monitoring capabilities are designed to minimise waste, boost operational performance, and drive cost efficiencies. The addition of Maturix's technology is expected to complement Verifi's system, particularly in optimising concrete placement on construction sites. Since 2019, Maturix and Saint-Gobain have collaborated successfully, and they are currently developing a joint product offering. Earlier this year, Saint-Gobain completed the acquisition of FOSROC, a construction chemicals company, which further solidified Saint-Gobain's position in the global market, enhancing its capabilities in the construction chemicals sector. "Saint-Gobain acquires Maturix to expand digital construction reach" was originally created and published by World Construction Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?
Novo Nordisk has been actively pursuing licensing deals over the past six months. These have helped the company improve its pipeline in its most important area. There are other good reasons to consider investing in Novo Nordisk right now. 10 stocks we like better than Novo Nordisk › It wasn't so long ago that Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, seemed to be firing on all cylinders. However, the past year has been challenging for the drugmaker. One reason behind its poor performance over the trailing-12-month period is that it has encountered clinical setbacks. CagriSema, an investigational weight loss medicine, performed well in phase 3 studies, but not quite as well as management had promised. Elsewhere, Novo Nordisk's biggest rival in this area, Eli Lilly, has registered significant clinical wins that arguably put it ahead in this fast-growing market. Still, Novo Nordisk hasn't said its last word yet. The company has recently made significant moves to strengthen its anti-obesity pipeline. Should investors buy the stock following these developments? On June 11, Deep Apple Therapeutics, a privately held biotech company, announced a licensing deal with Novo Nordisk. The former will utilize its proprietary platform, which leverages a virtual library powered by artificial intelligence (AI) to identify promising compounds rapidly. Deep Apple will aim to optimize novel compounds for obesity and other related diseases, and will receive up to $812 million, including an up-front payment and milestones for clinical and regulatory achievements. While it's too early to celebrate this deal -- it's still brand-new and hasn't led to any significant wins yet -- it's worth pointing out that Novo Nordisk has penned several such agreements since the CagriSema setback. One of the more promising of these agreements was with United Biotechnology, a subsidiary of the China-based company United Laboratories International Holdings. Novo Nordisk dished out an up-front payment of $200 million (not to mention potential milestone payments of up to $1.8 billion) to acquire UBT251, a triple agonist -- that is, a medicine that mimics the action of three separate gut hormones: GLP-1, GIP, and glucagon. Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple agonist. So, with this acquisition, Novo Nordisk is trying to catch up to its longtime competitor. This move, along with others, has helped expand Novo Nordisk's weight-management pipeline. Could that help the stock bounce back? In my view, Novo Nordisk's stock is attractive regardless of its recent shopping spree. Here's one reason. Its forward price-to-earnings (P/E) ratio is 19.6 at this writing, while the average for the healthcare industry is 16.2. Though that means Novo Nordisk is trading at a premium compared to its peers, its financial results justify that difference. In the first quarter, the company's net sales jumped 19% year over year to 78.1 billion Danish kroner ($12.1 billion), while its earnings per share rose by 15% to 6.53 DKK ($1). Revenue and earnings growth in that range is above what's considered "good" for a pharmaceutical company, especially one of this size. Perhaps Novo Nordisk was due for a sell-off -- its forward P/E looked extremely high a year ago. However, at current levels, shares now appear far more attractive, given the company's strong financial results. And when we take into account its pipeline and the recent deals it's made, Novo Nordisk looks even more promising -- the weight-management market is on an incredible growth path. Other than Eli Lilly, no company should seriously challenge Novo Nordisk anytime soon. In addition to its licensing deals, the Denmark-based drugmaker has promising, internally developed candidates. Novo Nordisk has just announced that it will start phase 3 studies for amycretin, an investigational weight loss product with both oral and subcutaneous formulations; this product delivered encouraging results in early-stage studies. Meanwhile, the company asked the U.S. Food and Drug Administration to approve an oral formulation of semaglutide (the active ingredient in Wegovy). In addition to its core area of expertise, Novo Nordisk has made a point of developing medicines in other fields, and has several promising candidates across various diseases. For all these reasons the stock looks like a buy at current levels, despite the challenges the company has faced in the past year. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!* Now, it's worth noting Stock Advisor's total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy? was originally published by The Motley Fool
Yahoo
3 days ago
- Business
- Yahoo
Novo Nordisk Reclaims Top Spot in Europe by Market Value
Novo Nordisk A/S (NYSE:NVO) is among the best bear market stocks to buy according to analysts. Novo Nordisk A/S (NYSE:NVO) has reclaimed its crown as Europe's most valuable publicly traded company, surpassing German software giant SAP SE (ETR:SAPG). With a market capitalization of $355.904 billion, the giant's stock surged by nearly 10% in the last five days. Two major developments have taken place in recent days. Firstly, Novo Nordisk A/S (NYSE:NVO) has revealed its plan to advance its amycretin treatments into Phase 3 clinical trials for weight management. By the first quarter of 2026, the company expects to launch a Phase 3 development program for amycretin aimed at overweight or obese adults. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. Secondly, the Financial Times reported that activist hedge fund Parvus Asset Management has purchased shares of the company, which further boosted investor confidence. Moves like these signal that Novo Nordisk A/S (NYSE:NVO) is truly a leader in the market. Novo Nordisk A/S (NYSE:NVO) is a Denmark-based company that engages in the research and development, manufacture, and commercialization of pharmaceutical products. Founded in 1923, it has two main segments: Diabetes and Obesity Care, and Rare Diseases. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-06-2025
- Business
- Yahoo
NVO Stock up on Plans to Advance Obesity Candidate Amycretin
Novo Nordisk NVO announced plans to advance amycretin, for weight management, into late-stage development. Amycretin is being developed for subcutaneous and oral administration. Shares of this Denmark-based company gained 2.95% on June 12, following the announcement. Oral amycretin is a novel, unimolecular co-agonist of both GLP-1 and amylin receptors being developed by Novo Nordisk to provide an efficacious and convenient treatment for obesity and type 2 diabetes in adults. NVO decided to advance the candidate into phase III based on feedback received from regulatory authorities following end-of-phase II interactions for subcutaneous and oral amycretin in weight management. A phase I study evaluated the single-ascending dose and multiple-ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks. A phase Ib/IIa study investigated the safety, tolerability, pharmacokinetics, and proof-of-concept of once-weekly subcutaneous amycretin in people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks. The phase III program on amycretin is planned to be initiated during the first quarter of 2026. Buoyed by the stupendous success of its blockbuster semaglutide products, Wegovy (obesity) and Ozempic (diabetes), NVO is now developing several next-generation candidates in its pipeline, especially targeting the lucrative U.S. market. CagriSema, a fixed-dose combination of a long-acting amylin analogue and Wegovy, is the most advanced candidate in Novo Nordisk's obesity pipeline. Novo Nordisk will present full results from the phase III REDEFINE 1 and 2 studies on CagriSema shortly. Management stated that the REDEFINE 1 and 2 studies will provide insights into the transformational potential of CagriSema. The FDA accepted Novo Nordisk's regulatory application, seeking the approval of oral semaglutide 25 mg for obesity, for review. A final decision from the regulatory body is expected around the turn of the year. Year to date, Novo Nordisk's shares have lost 4.7% against the industry's growth of 2.9%. Image Source: Zacks Investment Research The stock price was under pressure at the start of the year due to recent market challenges. Stiff competition in the obesity market from its arch-rival, Eli Lilly LLY, along with pipeline and regulatory setbacks, weighed on the share price. We note that NVO's semaglutide drugs have only been off the FDA's supply shortage list since February 2025. Eli Lilly markets its tirzepatide medicines as Mounjaro for T2D and Zepbound for obesity. Like NVO, LLY is also evaluating several next-generation weight loss candidates. LLY, too, has achieved stupendous success for its obesity drugs. Nonetheless, NVO stock has witnessed some recovery this week. Novo Nordisk gained 5% on June 10, following a report that activist hedge fund Parvus Asset Management is building a stake in the company. Per the Financial Times, this London-based hedge fund is raising its stake in NVO to influence the appointment of the company's new chief executive officer (CEO). Last month, shares of the company dipped after it announced that CEO Lars Fruergaard Jørgensen would step down from his position following a mutual agreement with the company's board. Novo Nordisk currently carries a Zacks Rank #3 (Hold). A couple of better-ranked large-cap pharma stocks are Novartis NVS and Bayer BAYRY, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.46 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 35 cents to $9.02 during this timeframe. The stock has risen 27% so far this year. BAYRY's 2025 EPS estimate has increased from $1.19 to $1.25 for 2025 over the past 60 days, while that for 2026 has gone up from $1.28 to $1.31 over the same timeframe. Year to date, shares of Bayer have surged 65.1%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
